Drug Profile
BMD 1141
Alternative Names: BMD-1141; BMD-1341Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator University of Arkansas System
- Developer BiologicsMD
- Class Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Parathyroid hormone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alopecia
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Alopecia in USA (SC, Injection)
- 28 Sep 2023 No recent reports of development identified for research development in Alopecia in USA (Topical)
- 08 Sep 2021 BMD 1141 is still in preclinical trials for Alopecia in USA (BiologicsMD pipeline, September 2021)